+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Plasma Fractionation Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797823
The global plasma fractionation market value was USD 26.2 billion in 2022, 2031 driven by the growing demand for plasma-derived therapies across the globe. The market size is anticipated to grow at a CAGR of 6.7% during the forecast period of 2023-2031 to achieve a value of USD 47 billion by 2031.

Plasma Fractionation: Introduction

Plasma fractionation is a process by which various proteins and other components are separated from human blood plasma for the production of therapeutic products. These products, derived from plasma proteins, play a crucial role in treating a wide range of life-threatening diseases and conditions, including immune deficiencies, haemophilia, and other bleeding disorders. Plasma-derived therapies are also utilized for critical care applications, such as emergency treatments for trauma, burns, and shock, as well as in surgical procedures.

Plasma Fractionation Market Scenario

The global plasma fractionation market has experienced significant growth in recent years, fuelled by factors such as the increasing prevalence of chronic diseases, an aging population, and a growing demand for plasma-derived therapies. The market has also been driven by technological advancements in plasma fractionation techniques, which have improved the efficiency, safety, and scalability of the process. Additionally, a supportive regulatory environment and increasing investments in research and development have further contributed to the market's expansion.

The adoption of plasma-derived therapies has been increasing steadily due to factors such as the rising prevalence of chronic diseases, an aging population, and a growing demand for these therapies. Technological advancements in plasma fractionation techniques, which have improved the efficiency, safety, and scalability of the process, have further contributed to the market's expansion.

North America: The largest market for plasma fractionation, driven by factors such as the high prevalence of chronic diseases, advanced healthcare infrastructure, and a strong focus on the development and adoption of plasma-derived therapies.

Europe: The second-largest market, with increasing demand for plasma fractionation due to a growing awareness of the importance of these therapies and supportive regulatory frameworks.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly aging population, increasing prevalence of chronic diseases, and growing investments in healthcare infrastructure.

Plasma Fractionation Market Segmentations

Market Breakup by Product

  • Immunoglobulins
  • Coagulation Factor Concentrates
  • Albumin
  • Protease Inhibitor
  • Others

Market Breakup by Method

  • Centrifugation
  • Depth Filtration
  • Chromatography
  • Others

Market Breakup by Application

  • Neurology
  • Hematology
  • Oncology
  • Immunology
  • Pulmonology
  • Others

Market by End User

  • Hospitals and Clinics
  • Clinical Research Laboratories
  • Academic Institutes
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Plasma Fractionation Market

Some key trends of the market are as follows:
  • Growing demand for immunoglobulins: Immunoglobulins represent the largest segment of the plasma fractionation market, driven by their widespread use in the treatment of immune deficiencies and other diseases
  • Technological advancements: The development of novel plasma fractionation techniques, such as chromatography and filtration, has improved the efficiency and safety of the process, supporting market growth
  • Expanding indications for plasma-derived therapies: The ongoing research and development efforts are leading to new indications for plasma-derived therapies, further fueling market growth

Plasma Fractionation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • CSL Plasma LLC
  • Grifols, S.A
  • Takeda Pharmaceutical Company Limited
  • Biotest Group
  • Baxter International Inc
  • LFB S.A
  • GC Pharma
  • Emergent Biosolutions
  • Japan Blood Products Organisation

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Plasma Fractionation Market Overview
3.1 Global Plasma Fractionation Market Historical Value (2016-2022)
3.2 Global Plasma Fractionation Market Forecast Value (2023-2031)
4 Global Plasma Fractionation Market Landscape
4.1 Global Plasma Fractionation Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Plasma Fractionation Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Method
4.2.3 Analysis by Applications
5 Global Plasma Fractionation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Plasma Fractionation Market Segmentation
6.1 Global Plasma Fractionation Market by Product
6.1.1 Market Overview
6.1.2 Immunoglobulins
6.1.3 Coagulation Factor Concentrates
6.1.4 Albumin
6.1.5 Protease Inhibitor
6.1.6 Others
6.2 Global Plasma Fractionation Market by Method
6.2.1 Market Overview
6.2.2 Centrifugation
6.2.3 Depth Filtration
6.2.4 Chromatography
6.2.5 Others
6.3 Global Plasma Fractionation Market by Application
6.3.1 Market Overview
6.3.2 Neurology
6.3.3 Hematology
6.3.4 Oncology
6.3.5 Immunology
6.3.6 Pulmonology
6.3.7 Others
6.4 Global Plasma Fractionation Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Clinical Research Laboratories
6.4.4 Academic Institutes
6.4.5 Others
6.5 Global Plasma Fractionation Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Plasma Fractionation Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Plasma Fractionation Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Plasma Fractionation Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Plasma Fractionation Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Plasma Fractionation Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 CSL Plasma LLC
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Grifols, S.A.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Takeda Pharmaceutical Company Limited
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Biotest Group
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Baxter International Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 LFB S.A.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 GC Pharma
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Emergent Biosolutions
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Japan Blood Products Organisation
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Plasma Fractionation Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Csl Plasma LLC
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Biotest Group
  • Baxter International Inc.
  • Octapharma AG
  • Kedrion S.P.A
  • Lfb S.A.
  • Biotest AG
  • Sanquin
  • Bio Products Laboratory Ltd.
  • Intas Pharmaceuticals Ltd.
  • Gc Pharma
  • Emergent Biosolutions
  • Japan Blood Products Organisation



Table Information